Galderma Jumps Into Dermal Filler Device Market With Q-Med Offer

Dermatology drug maker Galderma will be able to offer Q-Med’s Restylane dermal filler device alongside its Azzalure botulinum toxin for wrinkle treatment after acquiring Q-Med for up to $1.1 billion.